

Anna Bagnato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5874551/publications.pdf>

Version: 2024-02-01

112
papers

5,786
citations

61857

43
h-index

76769

74
g-index

112
all docs

112
docs citations

112
times ranked

4855
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 157.	3.5	5
2	YAP and endothelin-1 signaling: an emerging alliance in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 27.	3.5	23
3	Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. <i>Cell Reports</i> , 2021, 34, 108800.	2.9	15
4	Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/ β -arr1 Axis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 764375.	1.8	4
5	Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. <i>Communications Biology</i> , 2020, 3, 677.	2.0	13
6	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. <i>Cancer Letters</i> , 2020, 492, 84-95.	3.2	12
7	Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 584181.	1.8	35
8	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 600025.	1.3	9
9	In reply to SchÅfer <i>et al</i> : new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 1052-1055.	1.2	9
10	β -arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2019, 10, 3196.	5.8	40
11	Targeting Endothelin-1 Receptor/ β -Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach. <i>Frontiers in Endocrinology</i> , 2019, 10, 609.	1.5	19
12	New insights into the regulation of the actin cytoskeleton dynamics by GPCR/ β -arrestin in cancer invasion and metastasis. <i>International Review of Cell and Molecular Biology</i> , 2019, 346, 129-155.	1.6	16
13	Methods to Investigate β -Arrestin-1/ β -Catenin Signaling in Ovarian Cancer Cells. <i>Methods in Molecular Biology</i> , 2019, 1957, 393-406.	0.4	2
14	New Routes in GPCR/ β -Arrestin-Driven Signaling in Cancer Progression and Metastasis. <i>Frontiers in Pharmacology</i> , 2019, 10, 114.	1.6	38
15	Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. <i>Matrix Biology</i> , 2019, 81, 17-33.	1.5	23
16	hMENA is a key regulator in endothelin-1/ β -arrestin1-induced invadopodial function and metastatic process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3132-3137.	3.3	21
17	Endothelin-1 receptor drives invadopodia: Exploiting how β -arrestin-1 guides the way. <i>Small GTPases</i> , 2018, 9, 394-398.	0.7	12
18	Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 781-793.	1.2	21

#	ARTICLE	IF	CITATIONS
19	Blocking endothelin-1-receptor/ β 2-catenin circuit sensitizes to chemotherapy in colorectal cancer. <i>Cell Death and Differentiation</i> , 2017, 24, 1811-1820.	5.0	34
20	Targeting endothelin-1 receptor/ β 2-arrestin1 network for the treatment of ovarian cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 925-932.	1.5	9
21	β 2-arrestin1 at the cross-road of endothelin-1 signaling in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 121.	3.5	47
22	Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. <i>Life Sciences</i> , 2016, 159, 43-48.	2.0	25
23	Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer. <i>Life Sciences</i> , 2016, 159, 49-54.	2.0	13
24	Endothelin therapeutics in cancer: Where are we?. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R469-R475.	0.9	38
25	Endothelin A receptor drives invadopodia function and cell motility through the β 2-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. <i>Oncogene</i> , 2016, 35, 3432-3442.	2.6	53
26	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. <i>Oncotarget</i> , 2016, 7, 4009-4023.	0.8	49
27	Nuclear β 2-arrestin1 is a critical cofactor of hypoxia-inducible factor-1 α signaling in endothelin-1-induced ovarian tumor progression. <i>Oncotarget</i> , 2016, 7, 17790-17804.	0.8	33
28	Disrupting the endothelin and Wnt relationship to overcome chemoresistance. <i>Molecular and Cellular Oncology</i> , 2015, 2, e995025.	0.3	3
29	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. <i>Nucleic Acids Research</i> , 2014, 42, 2945-2957.	6.5	45
30	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti- α -Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 916-925.	1.9	21
31	Endothelin A Receptor/ β 2-Arrestin Signaling to the Wnt Pathway Renders Ovarian Cancer Cells Resistant to Chemotherapy. <i>Cancer Research</i> , 2014, 74, 7453-7464.	0.4	89
32	Endothelin-1 regulates hypoxia-inducible factor-1 α and -2 α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. <i>Life Sciences</i> , 2014, 118, 185-190.	2.0	19
33	β 2-Arrestin-1 Drives Endothelin-1-Mediated Podocyte Activation and Sustains Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 523-533.	3.0	63
34	The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. <i>Carcinogenesis</i> , 2014, 35, 840-848.	1.3	44
35	β 2-Arrestin 1 is required for endothelin-1-induced NF- κ B activation in ovarian cancer cells. <i>Life Sciences</i> , 2014, 118, 179-184.	2.0	64
36	Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 3144: PDZ-RhoGEF/ β 2-arrestin-1 interaction mediates endothelin A receptor-induced RhoA activation and cell motility in ovarian tumor cells. , 2014, , .		0
38	Endothelin 1 in cancer: biological implications and therapeutic opportunities. <i>Nature Reviews Cancer</i> , 2013, 13, 637-651.	12.8	282
39	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. <i>Journal of Molecular Medicine</i> , 2013, 91, 83-94.	1.7	63
40	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). <i>Gynecologic Oncology</i> , 2013, 130, 31-37.	0.6	20
41	Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. <i>Journal of Molecular Medicine</i> , 2013, 91, 395-405.	1.7	48
42	β 2-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β 2-catenin signaling. <i>Oncogene</i> , 2013, 32, 5066-5077.	2.6	79
43	Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis. <i>Current Oncology</i> , 2012, 19, 36-38.	0.9	25
44	The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future. <i>Current Pharmaceutical Design</i> , 2012, 18, 2720-2733.	0.9	7
45	The endothelin A receptor and epidermal growth factor receptor signaling converge on β 2-catenin to promote ovarian cancer metastasis. <i>Life Sciences</i> , 2012, 91, 550-556.	2.0	11
46	Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. <i>Life Sciences</i> , 2012, 91, 638-643.	2.0	15
47	Abstract 493: Endothelin-1 induces activation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. , 2012, , .		0
48	Abstract 3086: β 2-arrestin-1 acts as a nuclear transcriptional regulator of endothelin A receptor signalling to promote ovarian cancer progression. , 2012, , .		0
49	Role of the endothelin axis and its antagonists in the treatment of cancer. <i>British Journal of Pharmacology</i> , 2011, 163, 220-233.	2.7	103
50	Lost in translation: bridging the gap between cancer research and effective therapies. <i>Cell Death and Differentiation</i> , 2011, 18, 1082-1084.	5.0	1
51	Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 2350-2360.	3.2	167
52	Abstract 698: β 2-arrestin-1 as nuclear signalling element essential for endothelin A receptor-induced epithelial to mesenchymal transition and chemoresistance. , 2011, , .		0
53	Abstract 707: Acquisition of chemoresistance and epithelial to mesenchymal phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. , 2011, , .		0
54	Abstract 3473: Endothelin axis autocrine loop is positively regulated by the interplay between ET-1 and hypoxia-inducible factor-1 α in melanoma cells. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
55	The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 299, R395-R404.	0.9	25
56	Combination therapy of zibotentan with cisplatin and paclitaxel is an effective regimen for epithelial ovarian cancer. This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 676-681.	0.7	8
57	Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 782-787.	0.7	19
58	β -arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase. This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 796-801.	0.7	28
59	Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1 α in Melanoma Cells. <i>PLoS ONE</i> , 2010, 5, e11241.	1.1	50
60	Convergent pathways link the endothelin A receptor to the β -catenin: The β -arrestin connection. <i>Cell Cycle</i> , 2009, 8, 1461-1465.	1.3	11
61	β -Arrestin links endothelin A receptor to β -catenin signaling to induce ovarian cancer cell invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2806-2811.	3.3	159
62	Endothelin-1 Stimulates Lymphatic Endothelial Cells and Lymphatic Vessels to Grow and Invade. <i>Cancer Research</i> , 2009, 69, 2669-2676.	0.4	87
63	Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection. <i>Cell Cycle</i> , 2009, 8, 1462-3.	1.3	5
64	The endothelin axis in cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1443-1451.	1.2	172
65	The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. This article is one of a selection of papers published in the special issue (part 2 of 2) on Frontiers in Endothelin.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2008, 86, 473-484.	0.7	78
66	Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity. <i>Cancer Research</i> , 2007, 67, 6351-6359.	0.4	65
67	Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1 α in Human Melanoma Cells. <i>Cancer Research</i> , 2007, 67, 1725-1734.	0.4	84
68	ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2003-2011.	1.9	61
69	Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis. <i>Cells Tissues Organs</i> , 2007, 185, 85-94.	1.3	63
70	Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1483-1492.	1.9	73
71	Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 833-842.	1.9	74
72	Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. <i>Experimental Biology and Medicine</i> , 2006, 231, 1123-7.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. <i>Experimental Biology and Medicine</i> , 2006, 231, 1128-31.	1.1	18
74	ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. <i>Experimental Biology and Medicine</i> , 2006, 231, 1132-5.	1.1	7
75	Emerging role of the endothelin axis in ovarian tumor progression. <i>Endocrine-Related Cancer</i> , 2005, 12, 761-772.	1.6	80
76	Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells. <i>Cancer Research</i> , 2005, 65, 11649-11657.	0.4	161
77	Targeting Endothelin Axis in Cancer. , 2004, 119, 293-314.		17
78	Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression. <i>Cancer Research</i> , 2004, 64, 1436-1443.	0.4	115
79	Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells. <i>Clinical Cancer Research</i> , 2004, 10, 4670-4679.	3.2	62
80	Therapeutic Targeting of the Endothelin-A Receptor in Human Ovarian Carcinoma: Efficacy of Cytotoxic Agents is Markedly Enhanced by Co-administration with Atrasentan. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S132-S135.	0.8	7
81	Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion. <i>Journal of Biological Chemistry</i> , 2004, 279, 46700-46705.	1.6	91
82	Endothelin receptors as novel targets in tumor therapy. <i>Journal of Translational Medicine</i> , 2004, 2, 16.	1.8	96
83	Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S140-S143.	0.8	20
84	Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S136-S139.	0.8	12
85	Targeting Endothelin Receptor Type A in Human Cervical Carcinoma Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S72-S75.	0.8	5
86	The endothelin axis: emerging role in cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 110-116.	12.8	527
87	Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi's Sarcoma Cell Invasion and Tumor Growth in Vivo. <i>American Journal of Pathology</i> , 2003, 163, 753-762.	1.9	55
88	Emerging role of endothelin-1 in tumor angiogenesis. <i>Trends in Endocrinology and Metabolism</i> , 2003, 14, 44-50.	3.1	123
89	Endothelin-1 Decreases Gap Junctional Intercellular Communication by Inducing Phosphorylation of Connexin 43 in Human Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 41294-41301.	1.6	64
90	Therapies for cancer targeting endothelin receptors. <i>Drugs of the Future</i> , 2003, 28, 983.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma. <i>Cancer Research</i> , 2003, 63, 2447-53.	0.4	90
92	Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1 α in Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 27850-27855.	1.6	182
93	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. <i>Molecular Pharmacology</i> , 2002, 61, 524-532.	1.0	132
94	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. <i>Clinical Science</i> , 2002, 103, 302S-305S.	1.8	24
95	Endothelin-1 promotes proteolytic activity of ovarian carcinoma. <i>Clinical Science</i> , 2002, 103, 306S-309S.	1.8	31
96	Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma. <i>Clinical Science</i> , 2002, 103, 310S-313S.	1.8	9
97	ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth <i>in vitro</i> . <i>Clinical Science</i> , 2002, 103, 318S-321S.	1.8	21
98	Growth inhibition of cervix carcinoma cells <i>in vivo</i> by endothelin A receptor blockade. <i>Cancer Research</i> , 2002, 62, 6381-4.	0.4	67
99	Endothelin Receptor Blockade Inhibits Proliferation of Kaposi's Sarcoma Cells. <i>American Journal of Pathology</i> , 2001, 158, 841-847.	1.9	34
100	Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. <i>FASEB Journal</i> , 2000, 14, 2277-2283.	0.2	57
101	Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2000, 157, 1537-1547.	1.9	184
102	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization <i>In Vivo</i> . <i>American Journal of Pathology</i> , 2000, 157, 1703-1711.	1.9	322
103	The E5 Oncoprotein of Human Papillomavirus Type 16 Enhances Endothelin-1-Induced Keratinocyte Growth. <i>Virology</i> , 1998, 248, 1-5.	1.1	41
104	Endothelins as Autocrine Regulators of Tumor Cell Growth. <i>Trends in Endocrinology and Metabolism</i> , 1998, 9, 378-383.	3.1	74
105	The autonomous growth of human papillomavirus type 16-immortalized keratinocytes is related to the endothelin-1 autocrine loop. <i>Journal of Virology</i> , 1997, 71, 6898-6904.	1.5	12
106	Identification of the ETA Receptor Subtype That Mediates Endothelin-Induced Autocrine Proliferation of Normal Human Keratinocytes. <i>Biochemical and Biophysical Research Communications</i> , 1995, 209, 80-86.	1.0	29
107	Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. <i>Endocrinology</i> , 1992, 130, 1097-1102.	1.4	65
108	Gonadotropin-Induced Expression of Receptors for Growth Hormone Releasing Factor in Cultured Granulosa Cells*. <i>Endocrinology</i> , 1991, 128, 2889-2894.	1.4	32

#	ARTICLE	IF	CITATIONS
109	Modulation of adriamycin uptake by lonidamine in ehrlich ascites tumor cells. Experimental and Molecular Pathology, 1988, 49, 421-431.	0.9	19
110	Lonidamine-Induced Membrane Permeability and the Effect of Adriamycin on the Energy Metabolism of Ehrlich Ascites Tumor Cells. Annals of the New York Academy of Sciences, 1988, 551, 270-272.	1.8	0
111	Effect of adriamycin on electron transport in rat heart, liver, and tumor mitochondria. Experimental and Molecular Pathology, 1987, 46, 123-135.	0.9	39
112	Effect of hyperthermia on electron transport in ehrlich ascites tumor mitochondria. Experimental and Molecular Pathology, 1987, 46, 279-293.	0.9	3